Transgene SA Market Cap ($244.86 Million)
Market Cap & Net Worth: Transgene SA (TNG)
Transgene SA market cap. Transgene SA (PA:TNG) has a market capitalization of $244.86 Million (€209.45 Million) as of November 5, 2026. Listed on the PA stock exchange, this France-based company holds position #15545 globally and #227 in its home market, demonstrating a 11.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Transgene SA's stock price €0.76 by its total outstanding shares 278255465 (278.26 Million). Also see Transgene SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Transgene SA Market Cap History (2015–2026)
Transgene SA market cap history from 2015 to 2026. Data shows change from $785.59 Million to $246.58 Million (-11.49% CAGR). Check Transgene SA stock price for real-time trading data and today's change.
Transgene SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Transgene SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Transgene SA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
637.34x
Transgene SA's market cap is 637.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $850.03 Million | $2.35 Million | -$25.21 Million | 362.33x | N/A |
| 2017 | $897.63 Million | $2.10 Million | -$32.27 Million | 427.65x | N/A |
| 2018 | $865.91 Million | $1.33 Million | $8.03 Million | 648.62x | 107.89x |
| 2019 | $504.23 Million | $13.30 Million | -$18.80 Million | 37.92x | N/A |
| 2020 | $536.11 Million | $2.98 Million | -$18.45 Million | 179.84x | N/A |
| 2021 | $826.29 Million | $9.99 Million | -$20.00 Million | 82.69x | N/A |
| 2022 | $539.36 Million | $3.13 Million | -$32.81 Million | 172.54x | N/A |
| 2023 | $445.67 Million | $7.90 Million | -$22.33 Million | 56.41x | N/A |
| 2024 | $221.21 Million | $6.35 Million | -$33.97 Million | 34.82x | N/A |
| 2025 | $312.30 Million | $490.00K | -$37.52 Million | 637.34x | N/A |
Competitor Companies of TNG by Market Capitalization
Companies near Transgene SA in the global market cap rankings as of November 5, 2026. Also see TNG current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Transgene SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Transgene SA (2015–2026)
Market capitalization of Transgene SA from 2015 to today. Between 2015 and today, Transgene SA's market cap moved from $785.59 Million to $ 246.58 Million, with a yearly change of -11.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €246.58 Million | -21.04% |
| 2025 | €312.30 Million | +41.18% |
| 2024 | €221.21 Million | -50.36% |
| 2023 | €445.67 Million | -17.37% |
| 2022 | €539.36 Million | -34.72% |
| 2021 | €826.29 Million | +54.13% |
| 2020 | €536.11 Million | +6.32% |
| 2019 | €504.23 Million | -41.77% |
| 2018 | €865.91 Million | -3.53% |
| 2017 | €897.63 Million | +5.60% |
| 2016 | €850.03 Million | +8.20% |
| 2015 | €785.59 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Transgene SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.86 Million USD |
| MoneyControl | $244.86 Million USD |
| MarketWatch | $244.86 Million USD |
| marketcap.company | $244.86 Million USD |
| Reuters | $244.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more